Rare and orphan diseases
Expansion into new international biotech markets can be challenging. Unfamiliar regulations and licensing, coupled with language and cultural differences, can all be barriers to growth. If you’re considering venturing into Europe and beyond, our easy-to-follow guides, shaped by 30 years of expertise in the rare disease market, will assist you in navigating challenges and gaining a profound understanding of the complexities involved in launching orphan drugs into new markets. To learn more about how Sciensus can facilitate and support your Europan expansion, visit: Rare Diseases and Orphan Drugs

Blogs, Rare and orphan diseases
Mitigating Risks in Early Access Programs: A Guide for Biotech Companies

Blogs, Rare and orphan diseases
Planning your EU orphan drug stock management with Sciensus

Blogs, Rare and orphan diseases
Packaging and label compliance in Europe: Successfully navigating regulations with Sciensus

News, Rare and orphan diseases
Sciensus partners with Sentynl Therapeutics

Thought Leadership, Rare and orphan diseases
Launching successful patient support programs for rare disease patients across Europe

Thought Leadership, Rare and orphan diseases
Sciensus hosts a webinar with Fierce Biotech

Blogs, Rare and orphan diseases
Orphan drugs: How to avoid costly stock losses in Europe

Blogs, Rare and orphan diseases
Compassionate use programs in Europe: all you need to know

Blogs, Rare and orphan diseases
Out-licensing vs partnering: Strategies for accessing Europe